SCHEDULE: Zenas BioPharma: CEO Discloses Stake
Beneficial Ownership Filing
Leon O. Moulder, Jr., CEO of Zenas BioPharma, along with affiliated entities, has disclosed beneficial ownership of 5.09% of the company's common stock.
Summary
- Leon O. Moulder, Jr., in his capacity as CEO and Chairman of Zenas BioPharma, Inc., along with Tellus BioVentures, LLC and the Leon O. Moulder, Jr. Revocable Trust, has filed a Schedule 13D disclosing beneficial ownership of 3,220,880 shares of common stock, representing 5.09% of the outstanding shares.
- The filing details the history of acquisitions and shareholdings by the reporting persons, including direct holdings, stock options, and shares held by affiliated entities.
- The reporting persons acquired their initial stakes in Zenas BioPharma (Cayman) Limited prior to its IPO and have since made further open-market purchases and participated in private placements.
- Mr. Moulder's holdings include shares directly owned, shares underlying exercisable stock options, and shares held through Tellus BioVentures and the Revocable Trust, where he holds significant control.
- The reporting persons state their intention to hold the securities for general investment purposes and reserve the right to acquire or dispose of additional securities based on market conditions and company developments.
- Discussions regarding corporate governance, board composition, management, operations, and strategic alternatives are anticipated.
- The filing also references registration rights granted under a Shareholders Agreement and a PIPE Registration Rights Agreement related to past private placements.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting significant insider ownership and potential strategic discussions, but lacking specific operational or financial performance data.
Positives
- The CEO and affiliated entities have a significant beneficial ownership stake (5.09%) in Zenas BioPharma, indicating strong alignment with shareholder interests.
- The reporting persons have a history of investing in the company, including participation in private placements and open-market purchases, demonstrating continued commitment.
- The CEO's role as Chairman and CEO, combined with his substantial shareholding, suggests strong leadership and a vested interest in the company's success.
- Registration rights are in place, which can facilitate future liquidity for significant shareholders.
Negatives
- The filing does not contain specific financial performance data, making it difficult to assess the company's current financial health directly from this document.
- The disclosure of potential future discussions regarding strategic alternatives could imply that current strategies may not be sufficient or that the company is exploring significant changes.
Risks
- The reporting persons reserve the right to acquire or dispose of securities, which could lead to market volatility if significant transactions occur.
- Discussions regarding strategic alternatives could lead to uncertainty about the company's future direction.
- The filing does not provide details on the company's operational performance or future prospects, which are key risk factors for investors.
Future Outlook
The reporting persons intend to review their investment in Zenas BioPharma on a continuing basis and may adjust their holdings based on various factors. They also anticipate engaging in discussions regarding the company's governance, management, operations, and strategic plans, which could include exploring strategic alternatives.
Management Comments
- Mr. Moulder, in his capacity as Chief Executive Officer of the Issuer, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards.
- The Reporting Persons reserve the right to formulate in the future plans or proposals that may relate to or result in transactions described in Item 4 of Schedule 13D.
- The Reporting Persons may engage in discussions with management, the Board of Directors, other stockholders, and third parties regarding the company's governance, board composition, management, operations, business, assets, capitalization, financial condition, strategic plans, and future, as well as other matters.
- These discussions may include a review of options for enhancing stockholder value through strategic alternatives or operational/management initiatives.
Industry Context
StockSavvy.ai notes that Schedule 13D filings by key executives and affiliated entities are common in the biotechnology sector, often signaling significant insider conviction or potential strategic shifts. The focus on investment vehicles like LLCs and trusts is typical for managing personal and investment portfolios in this industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Shareholders Agreement | Fourth Amended and Restated Shareholders Agreement dated May 3, 2024, grants registration rights to stockholders. | 2024-05-03 | Provides mechanisms for liquidity and future sale of shares for significant holders. |
| Registration Rights Agreement | PIPE Registration Rights Agreement entered into on October 7, 2025, with PIPE Investors for resale of PIPE Shares. | 2025-10-07 | Ensures that shares purchased in the private placement can be registered for resale, providing liquidity. |
Related Party Transactions
- The Trust purchased 36,928 shares of Director and Officer Investor PIPE Shares for $769,948.80 in the October 7, 2025 Private Placement.
- Mr. Moulder is the CEO and Chairman of Zenas BioPharma, Inc., and has received stock options as part of his employment.
Stakeholder Impact
- Shareholders: The significant stake held by the CEO and affiliated entities may signal confidence, but potential future strategic shifts could impact share value.
- Employees: Discussions about management and strategic initiatives could lead to changes affecting employee roles and company direction.
- Management/Board: Mr. Moulder's dual role as CEO and significant shareholder influences corporate governance and strategic decision-making.
Next Steps
- The reporting persons may acquire additional shares or dispose of existing securities.
- Discussions may occur with management, the board, other stockholders, and third parties regarding company strategy and value enhancement.
- The company is obligated to file an initial registration statement for resale of PIPE Shares within 15 days of the PIPE Closing, subject to allowable delays.
Key Dates
| Date | Description |
|---|---|
| 2019-09-09 | Tellus BioVentures purchased 1,000,000 ordinary shares. |
| 2020-08-21 | Zenas Cayman granted Mr. Moulder a restricted stock award. |
| 2020-08-26 | Tellus BioVentures purchased 8,686,000 ordinary shares. |
| 2020-09-01 | Tellus BioVentures purchased Series Seed Convertible Preferred Shares. |
| 2020-11-01 | Mr. Moulder purchased Series A Convertible Preferred Shares. |
| 2021-11-01 | Tellus BioVentures purchased convertible promissory notes. |
| 2022-11-01 | Tellus BioVentures converted convertible promissory notes into Series B Preferred Shares. |
| 2022-11-01 | Mr. Moulder purchased Series B Preferred Stock. |
| 2023-07-01 | Zenas Cayman granted Mr. Moulder an option to purchase ordinary shares. |
| 2023-08-02 | Zenas Cayman de-registered and registered in Delaware as Zenas BioPharma, Inc. |
| 2024-05-03 | Fourth Amended and Restated Shareholders Agreement entered into. |
| 2024-06-10 | First vesting of 25% of shares from June 2025 option grant. |
| 2024-09-05 | Issuer effected a 1-for-8.6831 reverse stock split. |
| 2024-09-12 | First vesting of 25% of shares from IPO option grant. |
| 2024-09-16 | IPO consummated; Preferred Stock converted to Common Stock. |
| 2024-10-07 | Securities Purchase Agreement entered into for Private Placement. |
| 2024-10-09 | Private Placement (PIPE Closing) closed. |
| 2025-03-16 | Issuer's Annual Report on Form 10-K for year ended December 31, 2025 filed. |
| 2025-03-16 | Issuer's definitive proxy statement relating to its 2026 annual meeting of stockholders filed. |
| 2025-03-31 | Issuer issued Equity Offering Shares in a registered public offering. |
| 2025-06-10 | First vesting of 25% of shares from June 2025 option grant. |
| 2026-03-16 | Issuer's Annual Report on Form 10-K for year ended December 31, 2025 filed. |
| 2026-04-29 | Date of event requiring filing of this statement (options exercisable within 60 days). |
| 2026-05-05 | Date of filing of Schedule 13D and Joint Filing Agreement. |
Recommendation
holdThe filing indicates significant insider ownership and potential strategic discussions, but lacks concrete financial performance or forward-looking guidance to warrant a stronger recommendation. A 'hold' position allows for further observation of the company's strategic direction and operational execution.
Keywords
Schedule 13D, Zenas BioPharma, Leon O. Moulder, Jr., Beneficial Ownership, Common Stock, CEO, Chairman, Tellus BioVentures, Revocable Trust, SEC Filing, Securities, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.